Low-dose IL-2 therapy - a complex scenario that remains to be further explored

Nat Rev Rheumatol. 2017 Jun;13(6):386. doi: 10.1038/nrrheum.2017.71. Epub 2017 May 11.

Authors

Jens Y Humrich¹, Gabriela Riemekasten¹

Affiliation

¹ University Hospital Schleswig-Holstein, Campus Lübeck, Department of Rheumatology, Ratzeburger Allee 160, 23538 Lübeck, Germany.

PMID: 28490788
DOI: 10.1038/nrrheum.2017.71

No abstract available

Publication types

Comment

MeSH terms

CD4-Positive T-Lymphocytes
Humans
Immunotherapy
Interleukin-2*
Lupus Erythematosus, Systemic*
T-Lymphocyte Subsets

Substances

Interleukin-2